Ketamine is primarily metabolized to norketamine by hepatic CYP2B6 and CYP3A4-mediated N-demethylation. However, the relative contribution from each enzyme remains controversial. The CYP2B6*6 allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in ketamine metabolism. We examined the N-demethylation of individual ketamine enantiomers using human liver microsomes (HLMs) genotyped for the CYP2B6*6 allele, insect cell-expressed recombinant CYP2B6 and CYP3A4 enzymes, and COS-1 cell-expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant. Effects of CYP-selective inhibitors on norketamine formation were also determined in HLMs. The two-enzyme Michaelis-Menten model best fitted the HLM kinetic data. The Michaelis-Menten constants (K m ) for the highaffinity enzyme and the low-affinity enzyme were similar to those for the expressed CYP2B6 and CYP3A4, respectively. The intrinsic clearance for both ketamine enantiomers by the high-affinity enzyme in HLMs with CYP2B6*1/*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1/*6 genotype and CYP2B6*6/*6 genotype. The V max and K m values for CYP2B6.1 were approximately 160 and 70% of those for CYP2B6.6, respectively. N,N9N9-triethylenethiophosphoramide (thioTEPA) (CYP2B6 inhibitor, 25 mM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 mM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations. The degree of inhibition was significantly reduced in HLMs with the CYP2B6*6 allele (genedose P < 0.05). These results indicate a major role of CYP2B6 in ketamine N-demethylation in vitro and a significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity.
Introduction
Ketamine [(RS)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone] is a noncompetitive N-methyl-D-aspartate receptor antagonist. It has been used as an anesthetic agent and an adjuvant analgesic in subanesthetic doses to attenuate opioid tolerance and opioid-induced hyperalgesia (White et al., 1982; Subramaniam et al., 2004) . In addition, ketamine has displayed a rapid antidepressant effect and a preventive effect on postoperative interleukin-6 inflammatory response in clinical studies (Skolnick et al., 2009; Dale et al., 2012) . However, these therapeutic applications of ketamine are frequently restricted by considerable interindividual variabilities in drug efficacy and undesired psychotomimetic effects (White et al., 1982; Meyer et al., 2004) .
In most countries, ketamine is marketed as a racemic mixture consisting of equal amounts of (S)-and (R)-ketamine. (S)-Ketamine has an approximately 5-fold greater N-methyl-D-aspartate affinity and 4-fold greater analgesic potency, compared with (R)-ketamine, and is associated with less psychotomimetic effects (White et al., 1980; Mathisen et al., 1995; Ebert et al., 1997) . Furthermore, the plasma clearance of (S)-ketamine is approximately 22% faster in vivo (White et al., 1985) . However, no definitive evidence has been obtained from in vitro studies to support the stereoselective difference in ketamine clearance that is seen in vivo (Yanagihara et al., 2001; Portmann et al., 2010; Mossner et al., 2011) .
Ketamine is predominantly metabolized by hepatic cytochrome P450 (P450)-mediated N-demethylation to norketamine, a weakly active metabolite that has approximately one-third the anesthetic activity of its parent drug in rats (White et al., 1975) . Several studies using microsomes containing cDNA-expressed human P450 enzymes have shown the involvement of CYP2B6, CYP2C9, CYP2C19, and CYP3A4 in ketamine N-demethylation. Among these CYP enzymes, CYP2B6 exhibited the highest demethylation activity, followed by CYP3A4 (Yanagihara et al., 2001; Hijazi and Boulieu, 2002; Portmann et al., 2010) . In human liver microsomes (HLMs), Yanagihara et al. reported that CYP2B6 is the major enzyme responsible for (S)-and (R)-ketamine N-demethylation (Yanagihara et al., 2001 ). However, this was not confirmed by later studies, which identified that the primary contribution was from CYP3A4 (Hijazi and Boulieu, 2002; Mossner et al., 2011) .
CYP2B6 is responsible for the hepatic metabolism of several other clinically important drugs, including efavirenz, methadone, bupropion, propofol, and cyclophosphamide (Zanger et al., 2007; Turpeinen and Zanger, 2012) . It exhibits substantial interindividual variability with regard to both its catalytic activity and level of expression, which can be partially explained by the genetic variability of the highly polymorphic CYP2B6 gene. Among the currently described 30 alleles (www. cypalleles.ki.se/cyp2b6.htm), the CYP2B6*6 allele is the most prevalent and clinically important variant. This variant is characterized as a haplotype consisting of two linked nonsynonymous single nucleotide polymorphisms (SNPs), c.516G.T (rs3745274) and c.785A.G (rs2279343), which reduce the expression of functional enzyme (Hofmann et al., 2008) . The CYP2B6*6 allele has previously been associated with approximately 2-fold greater plasma concentration of efavirenz (Haas et al., 2004 ) and a 6-fold decrease in efavirenz 8-hydroxylation by HLMs (Xu et al., 2012) . Of interest, the influence of the CYP2B6*6 allele on in vitro drug metabolism appears to be substrate dependent, with bupropion and efavirenz being negatively affected, and cyclophosphamide 4-hydroxylation activity was generally found to be higher for the variant (Xie et al., 2006; Ariyoshi et al., 2011; Xu et al., 2012) . In contrast to these well-investigated CYP2B6 substrates, nothing is known regarding the impact of the CYP2B6*6 allele on ketamine N-demethylation.
The aim of this study was to evaluate the relative contribution of CYP2B6 and CYP3A4 to the N-demethylation of (S)-and (R)-ketamine using HLMs and expressed CYP2B6 and 3A4 isoforms and to assess the impact of CYP2B6*6 allelic variant on ketamine metabolism.
Materials and Methods
Chemicals. Boric acid, bromophenol blue, cyclopentylbromide, 2-chlorobenzonitrile, ethidium bromide, dimethyl sulfoxide BioReagent, ethylenediaminetetraacetic acid, DL-isocitric acid, isocitric dehydrogenase, (R,S)-ketamine hydrochloride, (S)-ketamine hydrochloride, sodium acetate, sodium pyrophosphate, D-(-)-tartaric acid, thioTEPA (N,N9N9-triethylenethiophosphoramide), and trizma base were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). Bovine serum albumin; Thermolpol reaction buffer; Taq DNA polymerase; BsrI, BsrBI, StyI, and SspI restriction enzymes; and corresponding reaction buffers were purchased from New England Biolabs (distributed by Genesearch, Arundel, QLD, Australia). Disodium hydrogen orthophosphate, dipotassium hydrogen orthophosphate, hydrochloric acid, magnesium chloride hexahydrate, sodium carbonate, and sodium dihydrogen orthophosphate were obtained from Ajax Chemicals (Auburn, NSW, Australia). NADP-disodium salt, potassium chloride, and triethylamine were purchased from Merck Pty. Ltd. (Kilsyth, VIC, Australia). Oligonucleotide primers and pUC19/HpaII DNA molecular weight marker were obtained from GeneWorks (Thebarton, SA, Australia). Acetonitrile, diethyl ether, hexane ethanol, and sucrose were purchased from Chem-supply (Gillman, SA, Australia). Agarose I was purchased by AMRESCO (distributed by Astral Scientific, Gymea, NSW, Australia). Omnigel-sieve agarose was manufactured by Edwards Instrument Co. (Narellan, NSW, Australia,). Ephedrine was obtained from Faulding Co. Ltd. (Torrensville, SA, Australia). Butylated hydroxytoluene was from MP Biochemicals (Irvine, CA). Deoxyribonucleoside triphosphate was purchased from Finnzymes (distributed by Genesearch). BigDye version 3.0 sequencing reagents were obtained from Applied Biosystems (Mulgrave, VIC, Australia). Maxwell 16 tissue DNA purification kits were purchased from Promega (Madison, WI).
Preparation of (R)-Norketamine, (S)-Norketamine, and (R)-Ketamine. Racemic norketamine hydrochloride was prepared starting from 2-chlorobenzonitrile. Treatment with cyclopentylmagnesium bromide in the presence of copper (I) bromide, followed by hydrolysis, gave the cyclopentyl-(2-chlorophenyl) ketone (Weiberth and Hall, 1987) . This was brominated with Nbromosuccinimide, followed by treatment with liquid ammonia to form an imine intermediate. Thermal rearrangement of the imine afforded (R,S)-norketamine (Fig. 1) . The structures of these chemicals were confirmed by 1 H and 13 C NMR spectra with use of a Varian Gemini (300 MHz) instrument (Agilent Technologies, Mulgrave, VIC, Australia). NMR spectra were recorded in CDCl 3 solution using tetramethylsilane (0 ppm) and CDCl 3 (77.0 ppm) as internal standards for 1 H and 13 C, respectively. Optical resolution of the enantiomers was accomplished through formation of the diastereomeric tartrate salts (Hong and Davisson, 1982) . (R)-ketamine hydrochloride was separated from (R,S)-ketamine hydrochloride through a modification of the published procedure for the resolution of (S)-ketamine (Steiner et al., 2000) .
Expressed Proteins and Monoclonal Antibodies. CYP2B6.1 and CYP2B6.6 protein variants were transiently expressed in COS-1 cells with use of pCMV-derived expression vectors, and microsomal fractions were prepared according to a previously described method (Lang et al., 2004) . Human P450 CYP2B6*6 and Ketamine Metabolism isoforms (CYP3A4 and CYP2B6) coexpressed with P450 reductase and cytochrome b 5 (Cyt b 5 ) in baculovirus-infected insect cells were commercially available from BD Gentest (North Ryde, NSW, Australia). Monoclonal antibodies inhibitory to human CYP3A4 and to human CYP2B6, antibodies against human CYP3A kit (WB-MAB-3A), and antibodies against human CYP2B6 kit (WB-2B6-PEP) for immunoblotting were also obtained from BD Gentest.
Liver Samples. Ethical approval was obtained from the Committee on the Ethics of Human Experimentation of the University of Adelaide and Human Ethics Committee of the Royal Adelaide Hospital. Human liver samples were donated by 23 patients undergoing partial hepatectomy for hepatic tumors. All liver samples were genotyped for the major CYP2B6 alleles by assays described below, and 11 liver tissues were selected on the basis of their CYP2B6*6 genotype. Characteristics of the 11 patients were as follows: (1) all were white; (2) ages ranged from 31 to 77 years; (3) six of eleven were male; 4) four patients carried CYP2B6*1/*1 genotype, four carried CYP2B6*1/*6 genotype, and three carried CYP2B6*6/*6 genotype; and (5) nine patients had normal clinical chemistry and hematology before surgery, one patient had high concentrations of lactate dehydrogenase (3.4 Â upper limit of normal) and transaminases (8 Â upper limit of normal), and one patient had high concentration of alanine transaminase (13.6 Â upper limit of normal). All tissue samples were frozen in liquid nitrogen and stored at 280°C until use.
CYP2B6 Genotyping. Genomic DNA was isolated from liver tissues with use of Maxwell 16 instrument with Maxwell 16 Tissue DNA purification kit according to the manufacturer's protocol. SNPs related to CYP2B6*5 (c.1459C.T, [rs3211371]), CYP2B6*6 (c.516G.T and c.785A.G), CYP2B6*7 (c.516G.T, c.785A.G and c.1459C.T), CYP2B6*8 (c.415A. G, [rs12721655]), and CYP2B6*13 (c.415A.G, c.516G.T and c.785A.G) allele were screened using previously described polymerase chain reactionrestriction fragment length polymorphism assays (Lang et al., 2004; Nakajima et al., 2007) . Genotypes of random samples were confirmed by DNA sequencing (BigDye, version 3.0).
Preparations of HLMs. HLMs were prepared using a previously described differential centrifugation method (Zanger et al., 1988) . Total protein content of the microsomes was quantified using a bicinchoninic acid colorimetric assay according to the manufacturer's protocol. Total P450 content of microsomes was measured using the carbon monoxide difference spectrum assay (Omura and Sato, 1964) . The CYP2B6 and CYP3A contents were determined using quantitative Western blot analysis with use of WB-2B6-PEP or WB-MAB-3A kits according to the manufacturer's protocol. The dilutions of primary (1°) and secondary (2°) antibodies for the detection of CYP3A and CYP2B6 in HLMs were 1°1: 2000/2°1:10000 and 1°1: 1000/2°1:1000, respectively.
Enzyme Kinetics in HLMs. Norketamine formation from separate (S)-and (R)-ketamine in HLMs was performed as follows. All incubations were performed in duplicate at 37°C in a shaking water bath. Incubation medium, in a final volume of 200 ml, consisted of 100 mg HLMs protein, NADPHregenerating system (1 mM NADP, 1 unit×ml 21 isocitrate dehydrogenase, 5 mM DL-isocitric acid, 5 mM magnesium chloride), and 25 mM of disodium phosphate buffer (pH 7.4). After a 3-minute preincubation, the reaction was initiated by the addition of various concentrations of ketamine [10 concentrations, final concentration ranges of 2.5 to 2000 mM of (S)-or (R)-ketamine], and terminated by the addition of 100 ml of saturated sodium carbonate after 30 minutes incubation. The mixture was then spiked with 15 ml of 50 mg/ml ephedrine (internal standard). Metabolites were extracted with 4 ml of 70:30 v/v hexane:ether for 20 minutes and back extracted with 100 ml of 0.1 M hydrochloric acid after centrifugation at 2000g for 10 minutes. The organic layer of the mixture was then aspirated, and 50 ml of the residue was injected for high-performance liquid chromatography (HPLC) analysis. The NADPHregenerating system was replaced by an equal volume of disodium phosphate buffer in incubations with norketamine standards. The (S)-and (R)-norketamine formations were linear with respect to incubation time (up to 30 minutes), microsomal protein content (up to 200 mg), and substrate concentration (2.5-2000 mM).
Enzyme Kinetics in cDNA-Expressed P450 Enzymes and Expressed CYP2B6 Variants. Baculovirus-infected insect cell microsomes containing cDNA-expressed CYP2B6 and CYP3A4 with coexpression of Cyt b 5 (in a final concentration of 5 pmol) were incubated in duplicate at five substrate concentrations for 30 minutes at 37°C. Each cDNA-expressed enzyme was preincubated with NADPH-regenerating system and disodium phosphate buffer for 3 minutes at 37°C before the addition of ketamine. The (S)-and (R)-ketamine concentration ranges for the expressed CYP2B6 and CYP3A4 were 10-150 mM and 100-1500 mM, respectively. These ranges were determined according to the mean K m1 and K m2 values for the HLMs with CYP2B6*1/*1 genotype.
N-Demethylations of (S)-and (R)-ketamine were also examined in CYP2B6.1-and CYP2B6.6-expressing COS-1 cell microsomes. The incubation conditions were identical to those described above.
Inhibition Studies with Chemical Inhibitors. The effects of chemical inhibitors selective for CYP2B6 (thioTEPA, 25 mM) and CYP3A (troleandomycin, 25 mM) on the formation of (S)-and (R)-norketamine from both low (equivalent to respective K m1 values for each genotype group) and high (equivalent to respective K m2 values for each genotype group) ketamine concentrations were studied in the 11 HLMs. The effects of chemical inhibitors at various final concentrations (5-100 mM) on norketamine formation were tested. The final concentration of each inhibitor (25 mM) was selected to optimize selective inhibition. Stock solutions of inhibitors were prepared in 0.1 M sodium phosphate buffer (pH 7.4) with 5% methanol. All components of the incubation medium except ketamine were preincubated with inhibitors or methanol control for 20 minutes at 37°C. The reaction was then initiated by the addition of substrate and terminated after 30 minutes incubation. Norketamine formation was quantified using the HPLC assay as described below.
Inhibition Studies with Monoclonal Antibodies against P450s. Monoclonal antibodies against CYP2B6 (MAB2B6) and CYP3A (MAB3A) were used in accordance with the manufacturer's recommendations. Antibodies (50 mg/100 mg HLMs protein) or inhibitor-free control were preincubated with an incubation medium containing HLMs, NADPH-regenerating system, incubation buffer, and 0.5 mM Tris buffer (pH 7.5) on ice for 20 minutes. The reaction was initiated by the addition of (S)-or (R)-ketamine (identical final concentrations as assays with chemical inhibitors) and terminated after 30 minutes.
HPLC Conditions. Norketamine formation was quantified using an HPLC assay with UV detection that was modified from a previously reported method (Chong et al., 2009) . In brief, separation of compounds was achieved in a 3-mm C8 reverse-phase column (150 Â 4.6 mm; LUNA; Phenomenex, Torrance, CA) with use of a mobile phase of 15% (v/v) acetonitrile and 0.05% triethylamine in 20 mM dipotassium phosphate (pH 3), and the flow rate was 0.8 ml/min. The column was protected by a guard cartridge system packed with 4 Â 3 mm C8 SecurityGuard cartridge (Phenomenex). Analytes were detected at 210 nm. The peak area was calculated using Shimadzu Class-VP software (version 6.12, SP2; Shimadzu, Kyoto, Japan). The retention times for ketamine, norketamine, and ephedrine were 11 minutes, 9 minutes, and 4 minutes, respectively. Norketamine formation was quantified using calibration curves consisting of eight standards of norketamine over the concentration range of 0.5-200 mM. Inter-assay and intra-assay variabilities were determined using the analysis of duplicates of quality-control norketamine samples at three different concentrations: low (2.5 mM), medium (25 mM), and high (80 mM). The inter-assay (n = 6) and intra-assay (n = 6) precision and inaccuracy of all quality-control samples were less than 10%. The precision and inaccuracy for the limit of quantification (n = 6) were below 10%.
Data Analysis. Eadie-Hofstee plots were used for analysis of enzyme kinetic data. The kinetic parameters (K m and V max ) were estimated using one-enzyme Michaelis-Menten model and a user-defined two-enzyme Michaelis-Menten
) with use of GraphPad Prism 5 software (San Diego, CA). Goodness of fit of data were compared between the two models. Intrinsic clearance (CL int ) was calculated as V max /K m . Inhibition data were expressed as a percentage of the corresponding controls. The differences in P450 protein content, kinetic parameters, and inhibitory effects on norketamine formation rate among CYP2B6*6 genotypes were determined by Jonckheere-Terpstra test using SPSS, version 19 (IBM, Armonk, NY). Correlations between CYP2B6 or CYP3A4 content and maximal norketamine formation rate were assessed using Spearman's rank correlation. Stereoselective differences in kinetic parameters and inhibitory effects were analyzed using two-tailed Wilcoxon matched-pairs signed rank test. Data are presented as median (range) (unless otherwise specified). The results were considered to be statistically significant when P , 0.05.
Results
CYP2B6 and CYP3A4 Protein Content. A significant reduction in CYP2B6 protein content was confirmed in HLMs with the CYP2B6*1/*6 (median, 18.9 pmol/mg protein; range, 13.0-32.0 pmol/mg protein; n = 4) and *6/*6 genotype (median, 10.4 pmol/mg protein; range, 8.1-12.2 pmol/mg protein; n = 3), compared with HLMs carrying the *1/*1 genotype (median, 23.4 pmol/mg protein; range, 21.2-37.6 pmol/mg protein; n = 4; Jonckheere-Terpstra test, P = 0.005). There was also approximately 5-fold variability in the CYP3A4 protein content among individual HLMs, but it was not correlated with CYP2B6*6 genotypes (P = 0.28).
Enzyme Kinetics in HLMs. Nonlinear Eadie-Hofstee plots indicated the participation of at least two enzymes in the Ndemethylation of (S)-and (R)-ketamine in HLMs (Fig. 2) . The twoenzyme Michaelis-Menten model provided a much better fit to the data, compared with the single-enzyme Michaelis-Menten model. The estimated values of kinetic parameters for the high-affinity/lowcapacity enzyme (V max1 , K m1 , and CL int1 ) and the low-affinity/highcapacity enzyme (V max2 , K m2 , and CL int2 ) are listed in Table 1 . The variability in kinetic parameters among three CYP2B6 genotypes is shown in Table 1 and Fig. 3 . For (S)-ketamine, significant gene-dose effects in K m1 and CL int1 values among three genotype groups were identified (P = 0.03 and 0.008, respectively). For (R)-ketamine, genedose effects in K m1 , CL int1 , and CL int2 values were found (P = 0.008; P = 0.001; and P = 0.008, respectively).
The maximal formation rates (V max , pmol/min/mg protein) and intrinsic clearance (CL int , ml/min/mg protein) of norketamine enantiomers by the high-affinity/low-capacity enzyme were better correlated with the CYP2B6 content (V max : Spearman r s = 0.7; P = 0.02; and r s = 0.56; P = 0.08 for (S)-and (R)-norketamine, respectively; CL int : r s = 0.81; P = 0.004; and r s = 0.80; P = 0.005 for (S)-and (R)-norketamine, respectively), compared with the CYP3A4 content (V max : r s = 20.05; P = 0.90; and r s = 0.33; P = 0.33 for (S)-and (R)-norketamine, respectively; CL int : r s = 0.19; P = 0.57; and r s = 0.37; P = 0.26 for (S)-and (R)-norketamine, respectively) (Figs. 4 and Fig. 5) . Conversely, the maximal norketamine formation rates and intrinsic clearance by the low-affinity/high-capacity enzyme were better correlated with CYP3A4 content (V max : r s = 0.55; P = 0.09; and r s = 0.39; P = 0.24 for (S)-and (R)-norketamine, respectively; CL int : r s = 0.71; P = 0.02; and r s = 0.80; P = 0.005 for (S)-and (R)-norketamine, respectively) but not with CYP2B6 content (V max : r s = 0.35; P = 0.30; and r s = 0.00; P . 0.99 for (S)-and (R)-norketamine, respectively; CL int : r s = 0.20; P = 0.56; and r s = 20.04; P = 0.92 for (S)-and (R)-norketamine, respectively).
There were no significant differences between (S)-and (R)-ketamine N-demethylation observed for any kinetic parameters (Wilcoxon signed ranks test, P . 0.07).
Enzyme Kinetics in cDNA-Expressed P450 Enzymes and Expressed CYP2B6 Variants. Table 2 shows the kinetic parameters of metabolism of (S)-and (R)-ketamine to norketamine by baculovirusinfected insect cell microsomes containing cDNA-expressed CYP2B6 and CYP3A4 coexpression of Cyt b 5 and by COS-1 cell-expressed CYP2B6.1 and CYP2B6.6 protein variants. The K m values for the expressed CYP2B6 were considerably lower than those for the expressed CYP3A4. The V max values were not substantially different among these three isoforms.
The mean K m value determined for (S)-ketamine N-demethylation by the insect cell-expressed CYP2B6 was significantly lower than that for (R)-ketamine (P = 0.03), and a greater mean CL int value was found for (S)-ketamine N-demethylation (P = 0.03), but not for the COS-1 cell-expressed CYP2B6.1 protein (P = 0.69). Differences in kinetic parameters were not apparent for the two enantiomers of ketamine with other expressed proteins (P . 0.05).
Inhibition Study. Figure 6 shows the effects of CYP2B6-and CYP3A-specific chemical inhibitors and inhibitory monoclonal antibodies on the N-demethylation of ketamine at low and high concentrations in HLMs carrying the three different CYP2B6 genotypes. At low ketamine concentrations (equivalent to the corresponding mean K m1 values for each CYP2B6 genotype group in HLMs kinetic assay, Fig. 2 . Example of kinetics of (R)-and (S)-norketamine formation by HLM (HLM#44, CYP2B6*1/*1). The data were best fitted using a modified two-enzyme Michaelis-Menten model. Inset: Eadie-Hofstee plots of enzyme kinetics in HLM44. V, norketamine formation velocity; V/S, reaction velocity/substrate concentration. Each value represents the mean 6 S.D.
TABLE 1
Two-enzyme Michaelis-Menten kinetic parameters for norketamine formation from (S)-and (R)-ketamine by the high-affinity/low-capacity enzyme (V max1 , K m1 , and CL int1 ) and the low-affinity/high-capacity enzyme (V max2 , K m2 , and CL int2 ) in 11 HLMs with CYP2B6*1/*1 (n = 4), *1/*6 (n = 4), and *6/*6 genotypes (n = 3)
pmol/min/pmol CYP (P450) mM ml/min/pmol CYP (P450) pmol/min/pmol CYP (P450) mM ml/min/pmol CYP (P450) 20-80 mM), the inhibitory effects of thioTEPA (25 mM) on norketamine formation in HLMs with CYP2B6*1/*1 genotype [67 and 62% for (S)-and (R)-norketamine, respectively] were significantly greater than those in HLMs with CYP2B6*1/*6 [39 and 35% for (S)-and (R)-norketamine, respectively] and CYP2B6*6/*6 genotypes (18% for both enantiomers; Jonckheere-Terpstra test, P = 0.007). Troleandomycin (25 mM) significantly inhibited (S)-and (R)-norketamine formations only in HLMs with CYP2B6*1/*6 genotype [P = 0.002; and 0.007 for (S)-and (R)-norketamine, respectively], with median values of percentage of inhibition less than 6%. At high ketamine concentrations (equivalent to the corresponding K m2 values, 300-850 mM), troleandomycin significantly diminished (S)-and (R)-norketamine formation by 30-46% (P , 0.0001); however, significant gene-dose effect on the degree of inhibition was not observed (Jonckheere-Terpstra test, P = 0.62). ThioTEPA had no effect on norketamine formation at these substrate concentrations [P = 0.38; and 0.50 for (S)-and (R)-norketamine, respectively]. MAB2B6 inhibited norketamine formation at low ketamine concentrations (P , 0.0001 for both enantiomers), with a higher median percentage inhibition in HLMs with CYP2B6*1/*1 [57 and 46% for (S)-and (R)-norketamine, respectively], compared with HLMs with CYP2B6*1/*6 [27 and 37% for (S)-and (R)-norketamine, respectively] and CYP2B6*6/*6 genotypes [19 and 30% for (S)-and (R)-norketamine, respectively]. MAB2B6 did not cause inhibition at high ketamine concentrations [P = 0.77; and 0.41 for (S)-and (R)-norketamine, respectively]. MAB3A4 inhibited norketamine formations by 30-50% at high substrate concentrations (P , 0.005), but it had no effect at low substrate concentrations. A significant gene-dose effect was not observed with MAB3A4 inhibition [P = 0.65; and 0.39 for (S)-and (R)-norketamine, respectively]. None of the four inhibitors exhibited stereoselective preference on norketamine formation at either substrate concentration.
Discussion
To our knowledge, the present study provides the first evidence that the CYP2B6*6 genetic variant has a major impact on the Ndemethylation of ketamine to norketamine in vitro, which is likely to be attributable to impairment in both enzyme-substrate binding and catalytic activity. The estimated K m values for (S)-and (R)-norketamine formation by the high-affinity/low-capacity enzyme and the low-affinity/high-capacity enzyme in HLMs with CYP2B6*1/*1 genotype were similar to those values for the insect cell-expressed CYP2B6 and CYP3A4, respectively. Therefore, the high-affinity/lowcapacity enzyme very likely corresponds to CYP2B6 and the lowaffinity/high-capacity to CYP3A4. This finding was also supported by the results of Spearman correlation analysis between the values of V max or CL int and P450 protein expression. The K m values for the high-affinity/low-capacity enzyme in HLMs with CYP2B6*1/*1 genotype were at least 3-fold and 2.7-fold lower, respectively, than those for HLMs with CYP2B6*1/*6 and CYP2B6*6/*6 genotypes. Similarly, significantly lower K m values for the COS-1 cell-expressed CYP2B6.1 protein, compared with the CYP2B6.6 variant, were observed. These results suggest an influence of the CYP2B6*6 allele on enzyme-ketamine binding. In addition to the increase in K m values, V max values for (S)-and (R)-norketamine formation in CYP2B6.6 variant significantly decreased by 41 and 35%, respectively, compared with CYP2B6.1, despite the minor difference in CYP2B6 expression levels between the two proteins. Therefore, the genetic impact of the CYP2B6*6 allele on V max values is likely to be attributable to an impairment in catalytic activity rather than in enzyme expression level. In human liver microsomal assays, however, no gene-dose effect in V max values was observed. This may be attributable to the low level of CYP2B6 as a percentage of total hepatic P450 content, and because these V max values were normalized to total microsomal P450 content, they might not accurately reflect the influence of the mutation in norketamine formation rate. As a consequence of the reduction in both enzyme-substrate binding and catalytic activity, intrinsic clearance rates of ketamine enantiomers by the high-affinity/low-capacity enzyme were decreased by at least 62% in HLMs with CYP2B6*1/*6 genotype and 84% in HLMs with CYP2B6*6/*6 genotype. This is consistent with the results for the COS-1 cell-expressed CYP2B6 protein variants. Surprisingly, a significant gene-dose effect of the CYP2B6*6 allele on the intrinsic clearance rates of (R)-ketamine by the low-affinity/high-capacity enzyme was observed, which is possibly attributable to a small sample size and large variability in CYP3A4 Fig. 3 . Influence of CYP2B6*6 allelic variant on kinetic parameters of (R)-and (S)-ketamine N-demethylation in HLMs by the high-affinity/low-capacity enzyme (A-C) and by the low-affinity/high-capacity enzyme (D-F). Line represents median. Gene-dose effects between CYP2B6 genotype and values of kinetic parameters were analyzed using Jonckheere-Terpstra test.
1268 Li et al. content between each HLM. The impact of the CYP2B6*6 allele on ketamine metabolism was further confirmed by inhibition assays, in which the inhibitory effect of thioTEPA and MAB2B6 on norketamine formation from low ketamine concentrations was substantially reduced in HLMs carrying CYP2B6*1/*6 (by 40-50%) and CYP2B6*6/*6 genotypes (by 60-70%), compared with HLMs with CYP2B6*1/*1 genotype.
The CYP2B6*6 allele has been previously associated with an increase in K m values and decrease in V max values for efavirenz 8-hydroxylation and bupropion 4-hydroxylation (Xu et al., 2012) . In contrast, it has also been associated with decreased K m values for cyclophosphamide 4-hydroxylation (Ariyoshi et al., 2011) . The substratedependent effects of the allele on enzyme-substrate binding and dmd.aspetjournals.org catalytic activity suggest that this influence of the CYP2B6*6 allele is more complicated than a decrease in enzyme expression. A previous report has shown that the c.516G.T polymorphism, one of the two nonsynonymous SNPs of the allele, induced high levels of an alternative splicing variant that may be responsible for altered enzyme activity (Hofmann et al., 2008) . However, whether the distinct substrate-dependent genetic impact is caused by the c.516G. T polymorphism and its molecular mechanism needs to be further investigated.
Another major finding of the current study is that the human liver microsomal N-demethylation of ketamine, at clinically relevant concentrations, is predominantly mediated by CYP2B6. By comparison, CYP3A4 appears to be a dominant contributor at much higher substrate concentrations. At low ketamine concentrations (20-80 mM) that are similar to the extrapolated peak hepatic concentration (approximately 50 mM) after an intravenous dose of 2 mg/kg of racemic ketamine for anesthesia (Hijazi and Boulieu, 2002) , substantial inhibition of (S)-and (R)-norketamine formation by the CYP2B6 inhibitor thioTEPA and MAB2B6 but minor inhibition by troleandomycin and MAB3A4 were found, suggesting a major participation of CYP2B6 but not CYP3A4 in ketamine N-demethylation. The effects of CYP2B6 inhibitors on norketamine formation in HLMs with CYP2B6*1/*1 genotype were in good agreement with previous investigations using pooled HLMs (Yanagihara et al., 2001; Hijazi and Boulieu, 2002; Mossner et al., 2011) . At high ketamine concentrations (300-850 mM), significant inhibition by troleandomycin and MAB3A4 but not by thioTEPA or MAB2B6 indicates that the predominant P450 isoform responsible for ketamine N-demethylation at high concentrations is more likely to be CYP3A4.
Previous studies using inhibition assays were inconsistent and inconclusive about the relative contribution of CYP3A4 to ketamine Ndemethylation at clinically relevant concentrations in HLMs. This discrepancy may be attributable to the selectivity of chemical inhibitors.
In the two studies that described a major role of CYP3A4 in ketamine metabolism, the CYP3A4 inhibitor ketoconazole at 10 mM exhibited the greatest inhibitory effects on norketamine formation from 25 or 50 mM of ketamine (Hijazi and Boulieu, 2002; Mossner et al., 2011 ). In contrast, another CYP3A4 inhibitor cyclosporin A and monoclonal antibodies against CYP3A4 failed to produce any inhibition on norketamine formation (Yanagihara et al., 2001; Mossner et al., 2011) . This discrepancy may be a result of ketoconazole also being a potent inhibitor of other P450 isoforms, including CYP2B6, CYP2C9, CYP2C19, and CYP2D6, with the half maximal inhibitory concentration and the inhibition constant for CYP2B6 being 2.3 and 1.4 mM, respectively (Perloff et al., 2009) . Thus, its effects on ketamine metabolism might be not only attributed to the inhibition of CYP3A4. In the current study, thioTEPA and troleandomycin at 25 mM were used as selective inhibitors of CYP2B6 and CYP3A4, respectively. ThioTEPA is a CYP2B6 chemical inhibitor with the highest selectivity, and troleandomycin has not been reported to inhibit other P450 isoforms (Turpeinen and Zanger, 2012) .
Differences in kinetic parameters for two enantiomers of ketamine were only observed in the insect cell-expressed CYP2B6 isoform with coexpression of Cyt b 5 but not in HLMs or COS-1 cell-expressed CYP2B6 enzyme. Accordingly, our results provide little evidence supporting the stereoselectivity in ketamine clearance that has been reported clinically. The K m value for (R)-ketamine metabolism was 1.3-fold higher than that for (S)-ketamine, leading to an approximately 27% decrease in the CL int value for (R)-ketamine metabolism, which is similar to the data previously reported by Portmann et al., who examined ketamine metabolism using the same recombinant CYP2B6 system (Portmann et al., 2010) . Of interest, the COS-1 cell-expressed CYP2B6.1 protein did not exhibit stereoselectivity in ketamine Ndemethylation. This conflicting result is possibly the consequence of the Cyt b 5 -induced conformational changes on CYP2B6 protein. Although this effect on CYP2B6 has not been reported, Cyt b 5 has been associated with conformational changes in CYP3A4 and CYP2C9 protein that can increase the collision between the substrate and the active-oxygen species at the active site of enzyme (Perret and Pompon, 1998; Locuson et al., 2007) .
The present results are consistent with the finding of our preliminary clinical data, that is, a significant reduction in the plasma norketamine to ketamine concentration ratio in the CYP2B6*6 carriers (unpublished data). Although further follow-up work is required to examine the influence of this variant on ketamine metabolism in vivo, our in vitro findings imply that genotyping of CYP2B6*6 allele may be useful in estimating ketamine clearance rate and for predicting drug interactions that might be attributed to CYP2B6 and CYP3A4 and, thus, may help to guide dosing decision and establish a safer dosage regimen. Because ketamine is a high hepatically cleared drug with low (;25%) oral bioavailability, this proposal would be more relevant when ketamine is given orally.
In conclusion, here, we demonstrate that the most common allelic variant of CYP2B6 gene, CYP2B6*6, is associated with the decrease in both enzyme ketamine binding and N-demethylation activity. To the best of our knowledge, this is the first report showing the impact of Single-enzyme kinetic parameters for the N-demethylation of (S)-and (R)-ketamine in insect cell-expressed CYP2B6 and CYP3A4 enzymes and COS-1 cell-expressed CYP2B6 variants a CYP2B6 genetic polymorphism on in vitro ketamine N-demethylation. Our data also show that CYP2B6 but not CYP3A4 is the major isoform responsible for the human liver microsomal ketamine N-demethylation at clinically relevant concentrations. Nevertheless, the role CYP3A4 increases as ketamine concentration increases. In addition, the ketamine metabolism to norketamine mediated by CYP2B6 and CYP3A4 was not stereoselective. . Effect of CYP2B6 and CYP3A4 inhibitors on norketamine formation from both low and high ketamine concentrations in HLMs with CYP2B6*1/*1 (n = 4), CYP2B6*1/*6 (n = 4), and CYP2B6*6/*6 (n = 3) genotypes. Low substrate concentrations were equivalent to the relative K m1 values; high substrate concentrations were equivalent to the relative K m2 values. MAB-3A, monoclonal antibody against CYP3A; MAB-2B6, monoclonal antibody against CYP2B6; TAO, troleandomycin. Results represent the mean 6 S.D. # Significant inhibition P , 0.05; **Significant gene-dose effect on inhibitory effects among three genotype groups, P , 0.01. 
